Adjunctive Intracoronary rhTNK-tPA During Primary PCI and Early Regional Left Ventricular Function in STEMI Patients With High Thrombus Burden: A Retrospective Cohort Study
Cardiology · 2026-10-28
DOI: 10.1159/crd/absag031 ↗Abstract
Background: Acute ST-segment elevation myocardial infarction (STEMI) with high thrombus burden often shows impaired myocardial perfusion despite successful epicardial recanalization. Intracoronary recombinant human TNK tissue-type plasminogen activator (rhTNK-tPA) may reduce microvascular obstruction and preserve ventricular function, but evidence is limited. Methods: This single-center retrospective cohort study included 136 STEMI patients with high thrombus burden undergoing primary PCI between May 2022 and February 2025. Patients receiving intracoronary rhTNK-tPA (n=62) were compared with controls receiving standard PCI alone (n=74). The primary endpoint was left ventricular regional wall motion status within 7 days after PCI, assessed by WMSI and normal ventricular wall motion. Secondary endpoints included cTFC, ST-segment resolution, final TIMI flow grade, and clinical and safety outcomes. Results: Baseline characteristics were generally comparable. The rhTNK-tPA group had lower WMSI values (P
EUVIMED